144 related articles for article (PubMed ID: 31424293)
1.
Berman RM; Kelada OJ; Gutsche NT; Natarajan R; Swenson RE; Fu Y; Hong J; Ho M; Choyke PL; Escorcia FE
Cancer Biother Radiopharm; 2019 Oct; 34(8):498-503. PubMed ID: 31424293
[No Abstract] [Full Text] [Related]
2. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
3. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
4. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
7. An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis.
Zhang Q; Han Z; Tao J; Zhao M; Zhang W; Li P; Tang L; Gu Y
Biomater Sci; 2018 Dec; 7(1):159-167. PubMed ID: 30417190
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
9. Current methods for the detection of glypican-3.
Xiao X; Huang Q; Lin X; Zahid KR; Huang X; Liu T; Zeng T
Anal Methods; 2024 Jan; 16(2):152-160. PubMed ID: 38108085
[TBL] [Abstract][Full Text] [Related]
10. Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments.
Li W; Xiao X; Li X; Xu Y; Ma L; Guo L; Yan C; Wu Y
Contrast Media Mol Imaging; 2018; 2018():9169072. PubMed ID: 30275801
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
Capurro M; Martin T; Shi W; Filmus J
J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
14. The development of a Glypican-3-specific binding peptide using
Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.
Allegretta M; Filmus J
Anticancer Agents Med Chem; 2011 Jul; 11(6):543-8. PubMed ID: 21554204
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.
Midorikawa Y; Ishikawa S; Iwanari H; Imamura T; Sakamoto H; Miyazono K; Kodama T; Makuuchi M; Aburatani H
Int J Cancer; 2003 Feb; 103(4):455-65. PubMed ID: 12478660
[TBL] [Abstract][Full Text] [Related]
17. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
Capurro MI; Xiang YY; Lobe C; Filmus J
Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626
[TBL] [Abstract][Full Text] [Related]
19. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
20. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.
Hanaoka H; Nakajima T; Sato K; Watanabe R; Phung Y; Gao W; Harada T; Kim I; Paik CH; Choyke PL; Ho M; Kobayashi H
Nanomedicine (Lond); 2015; 10(7):1139-47. PubMed ID: 25929570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]